Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system.
The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as make more informed treatment decisions.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott, Novo Nordisk ink deal for digital diabetes tools appeared first on MassDevice.
from MassDevice https://ift.tt/2E21Jix
Cap comentari:
Publica un comentari a l'entrada